BRIEF published on 01/20/2026 at 07:35, 16 days 23 hours ago Nicox announces its participation in several congresses in 2026 Glaucoma Ophthalmology Nicox NCX 470 Congress 2026
BRIEF published on 01/20/2026 at 07:35, 16 days 23 hours ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
PRESS RELEASE published on 01/20/2026 at 07:30, 17 days ago Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations Nicox to attend key ophthalmology conferences and present scientific data at AGS 2026 Annual Meeting. Management team available for meetings. Developing innovative eye health solutions Conference Scientific Data Ophthalmology Nicox Eye Health
BRIEF published on 12/16/2025 at 07:35, 1 month 20 days ago Nicox Finalizes Key Data for NCX 470 NDA Submission by H1 2026 Clinical Trials Ophthalmology Nicox NCX 470 NDA Submission
PRESS RELEASE published on 12/16/2025 at 07:30, 1 month 21 days ago Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 Nicox completes key data generation for NCX 470 new drug application submission in H1 2026, including clinical trial and stability data. U.S. and China submissions on track FDA Clinical Trials Nicox NCX 470 New Drug Application
BRIEF published on 10/23/2025 at 07:35, 3 months 13 days ago Nicox Releases First Half 2025 Financial Results Financial Results Debt Repayment Ophthalmology Cost Control NCX 470
PRESS RELEASE published on 10/23/2025 at 07:30, 3 months 14 days ago Nicox Provides First Half 2025 Financial Results Nicox provides first half 2025 financial results, expects NDA submissions for NCX 470 in 2026. Company aims to finance operations for 12 months and repay debts by 2026 Financial Results Debt Repayment Nicox NCX 470 NDA Submissions
BRIEF published on 10/02/2025 at 07:35, 4 months 3 days ago Nicox: Positive results for NCX 470 in the Denali study Clinical Trial Ophthalmology Nicox NCX 470 Intraocular Pressure
PRESS RELEASE published on 10/02/2025 at 07:30, 4 months 4 days ago Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Nicox's NCX 470 shows sustained efficacy with no new safety concerns in Denali trial. Data presented at upcoming ophthalmology conferences Nicox NCX 470 Denali Trial Ophthalmology Conferences Sustained Efficacy
BRIEF published on 09/04/2025 at 07:35, 5 months 1 day ago Nicox Plans Debt Repayment with NCX 470 Progress Debt Repayment Ophthalmology Licensing Nicox NCX 470
Published on 02/06/2026 at 00:57, 6 hours 33 minutes ago Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 7 hours 30 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 8 hours 15 minutes ago Amarc Further Expands Its Toodoggone Technical Team
Published on 02/05/2026 at 23:00, 8 hours 30 minutes ago Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/05/2026 at 21:00, 10 hours 30 minutes ago Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/06/2026 at 07:05, 25 minutes ago ANICAV's "Red Gold from Europe" @ BIOFACH with a delicious tasting programme.
Published on 02/06/2026 at 07:00, 30 minutes ago ABB Ltd: ABB launches new share buyback program of up to $2.0 billion
Published on 02/06/2026 at 07:00, 30 minutes ago Branicks Group AG: Ludwigshafen Technology Park fully let
Published on 02/06/2026 at 06:59, 31 minutes ago Aperam - Full year and fourth quarter 2025 results: “Aperam’s differentiated value chain delivers even in a weak macro environment”
Published on 02/05/2026 at 18:06, 13 hours 23 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
Published on 02/05/2026 at 18:00, 13 hours 30 minutes ago Information concerning the total number of voting rights and shares in the share capital as of January 30, 2026
